Skip to main content
Quest Diagnostics

Drug Monitoring, Assess Panel, Comprehensive, Qualitative, Urine

Test Code: 11878

The current list of drugs and/or metabolites analyzed, and their corresponding limits of detection are listed in the Table.

This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on the physician’s education, clinical expertise, and assessment of the patient.

 

Document FAQS.275 Version: 0

Version 0 effective 11/11/2024 to present

Related content

Drug Testing Podcasts
Audio Podcast
Phosphatidylethanol (PEth) blood test - Now available from Quest Diagnostics
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
Conference Presentation
Assessment oxycodone and metabolites in urine and oral fluid prescription drug monitoring programs
Conference Presentation
Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens
Conference Presentation
Prevalence of Opioid Use Among Gabapentin-Positive Urine Specimens

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.